Belite Bio (BLTE) is down about 4% in Friday trading, a move that fits a classic biotech setup: shares run hard into a catalyst, then soften as the market refocuses on financing-related supply and dilution. In recent weeks, Belite highlighted pivotal Phase 3 DRAGON trial success and positioned tinlarebant for a U.S. NDA filing in the second quarter of 2026, which helped fuel upside momentum heading into April. (investing.com)

A key overhang has been the company’s large capital raising tied to its Stargardt program, including a roughly $402 million underwritten public offering referenced in recent coverage and investor-focused summaries. Even when cash strengthens the balance sheet, the market often marks down the stock as new shares are issued and as investors anticipate incremental selling from holders who received stock in the deal. (tipranks.com)

Another near-term factor is that investors are now trading the calendar. Recent commentary around results and follow-up analysis indicates Belite refined its tinlarebant NDA submission window to the second quarter of 2026, shifting the focal point to execution steps (clinical study report finalization, rolling submission logistics) rather than a new efficacy surprise. That can reduce urgency for momentum buyers after a strong move, contributing to a pullback on no incremental positive headline. (investing.com)